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Abstract
INTRODUCTION: Patients with metastatic disease are considered incurable. We previously showed that nab-
paclitaxel (nanoparticle albumin-embedded paclitaxel) combined with anti–vascular endothelial growth factor A
(VEGF-A) antibody, bevacizumab, eradicates orthotopic small-sized breast tumors and metastasis. Here, we as-
sessed this therapy in two models of advanced (450-600 mm3) breast tumors and delineated VEGF-A–dependent
mechanisms of tumor resistance. METHODS: Mice with luciferase-tagged advanced MDA-MB-231 and MDA-MB-
435 tumors were treated with saline, nab-paclitaxel (10 or 30 mg/kg), bevacizumab (4 mg/kg), or combined drugs.
Lymphatic and lung metastases were measured by luciferase assay. Proinflammatory and survival pathways were
measured by ELISA, Western blot and immunohistochemistry. RESULTS: Nab-paclitaxel transiently suppressed
primary tumors by 70% to 90% but had no effect on metastasis. Coadministration of bevacizumab increased
the response rate to 99%, including 71% of complete responses in MDA-MB-231–bearing mice treated concur-
rently with 30 mg/kg of nab-paclitaxel. This combinatory regimen significantly reduced or eliminated preexisting
lymphatic and distant metastases in MDA-MB-231 and MDA-MB-435 models. The mechanism involves paclitaxel-
induced NF-κB pathway that upregulates VEGF-A and other tumor prosurvival proteins. CONCLUSIONS: Bevacizumab
prevents tumor recurrence and metastasis promoted by nab-paclitaxel activation of NF-κB pathway. Combination
therapy with high-dosed nab-paclitaxel demonstrates the potential to eradicate advanced primary tumors and pre-
existing metastases. These findings strongly support translating this regimen into clinics.
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Introduction
Chemotherapy is a frontline treatment of breast and other epithelial
malignancies, particularly those that are not resectable. Treatment of
measurable tumors with chemotherapeutic drugs results in three out-
comes: no response occurring in 5% to 10% of breast cancer (BC)
patients [1,2], a complete response (CR) occurring in 10% to 20%
of patients [1,2], and a partial response (PR) defined as more than
50% of the tumor reduction in response to therapy [1]. PR is the
most common outcome with 50% occurrence in patients in the neo-
adjuvant setting with noninvasive BC [1] and higher frequency in pa-
tients with metastatic disease, triple-negative, and therapy-resistant
tumors [3]. Incomplete responsiveness to cytotoxic drugs is one of
the main reasons for increased mortality due to uncontrolled tumor
growth. Delineating the mechanisms underlying PR holds the prom-
ise to identify the reasons for tumor resistance to chemotherapy and
the potential to improve the efficacy of anticancer drugs.
Abbreviations: ABX, Abraxane, or paclitaxel protein-bound particles for injectable sus-
pension, also abbreviated as nab-paclitaxel; Bev, bevacizumab, humanized anti–human
VEGF-A antibody, also known as Avastin; BC, breast cancer; i.p., intraperitoneally; i.v.,
intravenously; ILN, ipsilateral lymph node; LN, lymph node; MFP, mammary fat pad;
MTD, maximal tolerated dose; (p)-, phosphorylated form of protein; PBS, phosphate-
buffered saline; PBST, PBS containing Tween-20; RLU, relative light unit; TGD, tumor
growth delay; VEGF-A, vascular endothelial growth factor-A
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One of the reasons for tumor chemoresistance is overexpression of
P-glycoproteins that pump out cytotoxic drugs, thus preventing in-
tracellular accumulation of the lethal dose [4]. Another mechanism is
mediated by vascular endothelial growth factor A (VEGF-A), an an-
giogenic factor [5,6] that protects tumor cells from apoptosis through
autocrine activation of VEGF-A receptors expressed on tumor cells
[7]. VEGF-A is upregulated by various chemodrugs including pacli-
taxel [8], docetaxel [8], carboplatin [9], cisplatin [10], 5-fluorouracil
[11], dacarbazine [12], and anthracyclines [13]. Although the mech-
anism by which these drugs elicit VEGF-A expression is unclear, it
might occur through activation of NF-κB [14] and PI3K/AKT path-
ways [15] that are induced by chemotherapy in both malignant
[10,11] and endothelial cells [9]. The crucial role of VEGF-A in che-
moresistance was shown in both preclinical [16,17] and clinical stud-
ies [18,19] demonstrating superior efficacy of chemodrugs when
combined with anti–VEGF-A antibody. In particular, the combina-
tion of the anti–VEGF-A antibody, bevacizumab, with 5-fluorouracil,
leucovorin, oxaliplatin, or irinotecan, showed an additive or synergistic
effect [17]. The E2100 trial also showed that paclitaxel/bevacizumab
therapy increased a response rate and significantly prolonged patient
survival compared with paclitaxel treatment alone [20,21]. In addi-
tion, bevacizumab combined with other taxanes improved the out-
come in patients with ovarian tumors, although this benefit was
short-lived [18].
Of various taxanes, paclitaxel, a microtubule-stabilizing cytotoxic
agent, is widely used against metastatic and refractory tumors [22].
The clinical use of Cremophor-based paclitaxel (Taxol) has been re-
cently improved by formulating it as Cremophor-free, albumin-bound
130-nm nanoparticles coined nab-paclitaxel or Abraxane [23,24].
Nab-paclitaxel demonstrated several advantages over Cremophor-based
paclitaxel in clinical [22,25] and experimental [26,27] studies owing
to albumin encapsulation of the active component allowing for deliv-
ery of a high dose of paclitaxel without the use of solvent [28]. This
leads to dose-proportional pharmacokinetics, higher maximal tolerated
dose (MTD), and improved efficacy [22,29]. Nab-paclitaxel treatment
of metastatic BC patients demonstrated a higher response rate and
longer time to progression when compared with Cremophor-based
drug [28,29]. The superior efficacy of nab-paclitaxel versus conven-
tional paclitaxel was also shown in preclinical xenograft models dem-
onstrating increased incidence of tumor regressions, longer time to
recurrence, and extended survival [26]. These advantages are related
to the improved delivery of nab-paclitaxel compared with solvent-
based paclitaxel, leading to 33% increased intratumoral concentrations
and doubling of the MTD [26].
We recently demonstrated that nab-paclitaxel efficacy is further
improved by coadministration of anti–VEGF-A antibody [16]. It
was shown that combined nab-paclitaxel/bevacizumab therapy erad-
icated small-sized (150-200 mm3) orthotopic breast tumors in 40%
of the mice and reduced metastatic incidence [16]. Whereas these
results were encouraging, the models of small-sized tumors may not
adequately reflect the clinical challenges in patients who present with
advanced tumor burden and preexisting metastases. In the present
study, we allowed luciferase-tagged MDA-MB-231-Luc+ and MDA-
MB-435-Luc+ tumors to reach 450 to 600 mm3 before initiating
treatment. In these tumor models, 100% of the animals exhibited
preexisting metastases in both lung and lymph nodes (LN). The results
showed that bevacizumab combined with nab-paclitaxel at 10- and
30-mg/kg doses eradicated large 231-Luc+ tumors in 33% and 71%
of mice, respectively. Although no complete eradications were achieved
in the 435-Luc+ model, the combined treatment resulted in 94%
tumor inhibition and prolonged time to progression for more than
80 days. Importantly, in both models, the combined therapy substan-
tially decreased the incidence and the burden of preexisting pulmonary
and lymphatic metastases. Collectively, these data suggest that the
combination of bevacizumab and nab-paclitaxel can be effective in
eradicating advanced tumors and preexisting metastases in human
cancer patients.
Materials and Methods
Materials
Dulbecco modified Eagle medium and standard additives were ob-
tained from Lonza (Basel, Switzerland). Ketamine and xylazine were
from Phoenix Scientific (St Joseph, MO). Endotoxin-free sterile 150 mM
NaCl solution (saline) and protease inhibitors were fromSigma (St Louis,
MO). Matrigel was from BD Bioscience (Franklin Lakes, NJ).
Antibodies
Primary rabbit anti–Bcl-xL, anti-Akt, anti–p-Akt, anti-p44/42,
anti–p-p44/42 anti-p50, anti–p-p50, anti-p65, anti–p p65, anti–VEGF-
A, and anti–Bcl-2 antibodies were from Cell Signaling (Danvers, MA)
and Thermo Scientific (Waltham,MA). Mouse–anti–β-actin ( JLA20)
was from Developmental Studies Hybridoma Bank (Iowa City, IA).
Antirabbit and antimouse secondary antibodies were from Jackson
ImmunoResearch (West Grove, PA).
Study Drugs
Paclitaxel albumin-bound particles for injectable suspension (nab-
paclitaxel; Abraxane) was obtained from Abraxis BioScience (Los
Angeles, CA). Drugs were reconstituted in saline, prepared fresh daily,
and given within 1 hour of preparation. Bevacizumab (Avastin), hu-
manized anti–VEGF-A antibody, manufactured by Genentech (San
Francisco, CA), was obtained from a local pharmacy.
Human MDA-MB-231 and MDA-MB-435 Carcinoma Cell
Lines and Their Luciferase Derivatives
Luciferase-tagged subline ofMDA-MB-231, designated 231-Luc+, has
been extensively characterized in previous studies [16,30]. Luciferase-
tagged MDA-MB-435 subline, designated 435-Luc+, was a generous
gift from Dr Sierra (Universitaria de Bellvitge, Barcelona, Spain) and
described elsewhere [16,31]. Cells were cultured in Dulbecco modi-
fied Eagle medium supplemented with 5% fetal bovine serum and
standard additives and were subcultured by using 0.5 mM EDTA
diluted in phosphate-buffered saline (PBS).
Mouse Orthotopic Models of Human BC
Orthotopic 231-Luc+ and 435-Luc+ tumor models were previously
described [16,30]. Briefly, 4 × 106 cells suspended in 50% Matrigel
were implanted into the mammary fat pad (MFP) of 4- to 6-week-
old female SCID mice (National Cancer Institute, Frederick, MD).
Every 2 to 3 days, perpendicular tumor diameters were measured by
digital caliper and used to calculate tumor volume according to the
formula: volume = Dd 2π/6, where D indicates the larger diameter
and d indicates the smaller diameter. Animal care was in accordance
with institutional guidelines.
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Treatment with Nab-paclitaxel and Bevacizumab
Mice bearing advanced 231-Luc+ or 435-Luc+ tumors (450-600mm3)
were randomized into groups (7-16 per group) and treated with sa-
line (control), nab-paclitaxel alone (10 or 30 mg/kg, intravenously
[i.v.], daily for five consecutive days), bevacizumab alone (4 mg/kg,
intraperitoneally [i.p.], biweekly), or nab-paclitaxel combined with
bevacizumab. Nab-paclitaxel course was repeated twice with one
rest week between the courses. Bevacizumab treatment consisting of
4-mg/kg dose in saline (0.1 ml) injected i.p., biweekly, for the study’s
duration, began 24 hours after the first nab-paclitaxel injection. Con-
trol group received saline (0.1 ml), injected i.v. or i.p. on the same days
as nab-paclitaxel and bevacizumab treatments, respectively. Mice were
killed when tumor volumes in the control group reached 1800 mm3.
Metastasis was measured by luciferase activity in tissue extracts of the
axillary, brachial, inguinal LNs, and lungs.
Time Course of Metastatic Progression
Mice with orthotopic 231-Luc+ tumors were randomized into
groups (n = 4-8) and killed when average tumor volumes reached
100, 150, 250, 500, 1000, and 1800 mm3. Metastasis was determined
by measuring luciferase in tissues extracts of ipsilateral and contralateral
LNs, lung, brain, heart, kidney, MFP, and ovaries.
Optimization of the Combined
Nab-paclitaxel/Bevacizumab Regimen
Mice with orthotopic 435-Luc+ tumors were randomized into four
groups (n = 8 per group) when tumor volume reached 450 mm3.
Group 1 received saline; group 2 was treated with three courses of
nab-paclitaxel (10 mg/kg) followed by bevacizumab administrated
after cessation of chemotherapy; group 3 was concurrently treated with
nab-paclitaxel and bevacizumab, with both drugs being discontinued
on cessation of chemotherapy; and group 4 was concurrently treated
with nab-paclitaxel and bevacizumab with continued bevacizumab
treatment for the study’s duration. Nab-paclitaxel was administered
for three courses with one rest week between courses. Bevacizumab
was administered biweekly (i.p.) at 4 mg/kg. The study was terminated
40 days after the third nab-paclitaxel course.
Determination of Metastatic Burden
Luciferase activity was determined as previously described [16].
Briefly, tissues were homogenized in ice-cold cell culture lysis reagent
buffer (Promega, Madison, WI) containing protease inhibitors. Lu-
ciferase Assay Reagent (50 μl) was mixed with lysates (10 μl) fol-
lowed by luminescence detection using a luminometer (Berthold,
Germany). Luminescence of buffer alone was subtracted from the
results. Data are expressed as relative light units (RLUs) normalized
per milligram of protein. Extracts with luminescence of 800 RLUs
above background were rated as positive for metastasis.
Analysis of Cytokine Production Stimulated by Nab-paclitaxel
231-Luc+ cells were seeded at a density of 4 × 105 per well and
treated with 2.5, 5, 7.5, 10, or 30 nM of nab-paclitaxel for 72 hours,
followed by collection of the conditioned medium. Cytokines were
measured using the Linco High Sensitivity Human Cytokine Kit
(Millipore, Billerica, MA) according to the manufacturer’s instruc-
tions. Plates were quantified using the Luminex-100 system with
Beadview software version 1.7 (Luminex, Austin, TX). Cytokine pro-
duction was expressed as picograms per milliliter or nanograms per
milliliter normalized per 1 × 106 cells. Each experimental condition
was tested in triplicate and reproduced in two separate experiments.
Western Blot Analysis
Equal protein amounts of lysates from individual mice were com-
bined per group for Western blot analysis of 231-Luc+ tumors. Lysates
of 231-Luc+ cells treated with 0, 2.5, 5, 10, or 30 nM nab-paclitaxel
were harvested after 8, 24, and 48 hours in lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
0.1% SDS, phosphatase, and protease inhibitors). Proteins were sepa-
rated in 10% to 12% SDS–polyacrylamide gel and transferred onto
nitrocellulose membranes followed by overnight incubation with pri-
mary antibodies against NF-κB p50, p-p50, NF-κB p65, p-p65, p44/42,
p-p44/42, Akt, p-Akt, Bcl-xL, Bcl-2, and β-actin. Membranes were
incubated for 1 hour with HRP-conjugated secondary antibody be-
fore development with ECL (Pierce, Rockford, IL). Protein bands
were visualized using a Fujifilm LAS-3000 camera (Fujifilm, Valhalla,
NY), and densitometry was analyzed with Image-Reader LAS-3000
software (Valhalla, NY).
Immunohistochemistry
Frozen sections were fixed with 2% paraformaldehyde for 30 min-
utes and postfixed with ice-cold methanol. After rehydration in PBS
containing Tween-20 (PBST), sections were incubated for 2 hours
with primary antibodies (1:100 in PBST containing 0.5% bovine se-
rum albumin), washed for 10 minutes in PBST, followed by 1-hour
incubation with Cy3-conjugated antirabbit secondary antibodies.
Slides were mounted with Vectashield containing 4′,6-diamidino-
2-phenylindole (Vector Laboratories, Burlingame, CA). Images were
acquired at a constant exposure on a DP71 camera mounted on an
Olympus BX41 microscope using DP Controller software (Olympus,
Center Valley, PA).
Fluorescent Intensity Measurements
Tumors harvested from mice treated for 5 days with saline or nab-
paclitaxel (10 mg/kg) were stained with anti–VEGF-A antibodies. To
limit nonspecific background, a constant exposure was set to above
the level of tissue staining with secondary antibodies alone. Pixels
with intensity less than 3.6 were excluded from analysis as back-
ground. Fluorescent images were converted to 8-bit grayscale, and
the mean fluorescent intensity of VEGF-A staining from control-
and nab-paclitaxel–treated tumors (n = 3, 5 fields per section) ±
SEM was calculated using the Plot Profile function of the ImageJ
software (http://rsbweb.nih.gov/ij/). Plots of fluorescent staining in-
tensity were generated using the 3D Interactive Surface Plot function
of ImageJ.
Statistical Analysis
Statistical analysis was performed using SPSS 14.0 (SPSS, Chicago,
IL). Results are expressed as mean ± SE. Statistically significant differ-
ences in tumor volume among experimental groups were determined
by Student’s t test. The synergistic effect of combined therapy was as-
sessed using CompuSyn (CompuSyn, New York, NY), a software pro-
gram based on the calculations for synergism developed by Chou et al.
[32]. Statistically significant differences in incidence and burden of
metastases were analyzed by nonparametric Fisher exact and Wilcoxon
rank sum tests, respectively, because of the wide variability in meta-
static burden among individual mice within the group. Metastatic bur-
den values were log transformed and analyzed using variance test with
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Tukey follow-up comparison to assess the relationship between tumor
size and metastatic burden.
Results
Establishment of Advanced BC Model with
Preexisting Metastases
Unlike situations in the clinics, most experimental studies are
performed in animals bearing palpable or small-sized tumors with
volume of 50 to 150 mm3 (Table W1). The discrepancy between
a relative tumor size in cancer patients and experimental animals at
the time of the treatment might result in the significant difference in
tumor response to therapy. To better model tumor responses in hu-
man patients, we performed all studies in mice bearing tumors of
500 mm3 in volume. To determine the extent and distribution of me-
tastases in the advanced 231-Luc+ model, we measured kinetics of met-
astatic spread at different time points after tumor implantation. To
this end, LNs and major visceral organs were harvested from mice
(four to eight mice per group) bearing orthotopic 231-Luc+ tumors
of approximately 100, 150, 250, 500, 1000, and 1800 mm3. Even
at the earliest stage of tumor progression (tumor volume ∼100 mm3),
most mice (75%) had already LN metastases. By the time tumors
reached 250 mm3, 100% of the mice had metastases in both LN
and lungs (Figure 1 and Table 1). At the tumor volume of 485 mm3,
widespread distant metastasis was detected in the brain, heart, kidney,
contralateral MFP, and ovary (Table 1). This kinetics demonstrates
that therapies applied to tumors of 450 to 500 mm3 target preexist-
ing LNs and distant metastases rather than prevent their dissemination.
Because all experiments in this study were performed in mice with tu-
mors equal or larger than 500 mm3, this model of advanced BC with
preexisting metastases is much more akin to the clinical situation.
Nab-paclitaxel and Bevacizumab Act Synergistically
to Suppress Tumor Growth in Orthotopic Models
of Advanced BC
To analyze the effects of nab-paclitaxel/bevacizumab combination
therapy, we used previously described luciferase-tagged orthotopic
BC models, 231-Luc+ and 435-Luc+ [16,30]. Mice were treated with
10 mg/kg or the MTD of nab-paclitaxel in mice, 30 mg/kg [33].
Bevacizumab was administered i.p., 4 mg/kg, biweekly, for the ex-
perimental duration. Two independent experiments were performed
using 231-Luc+ and 435-Luc+ models with 7 to 16 mice per group
(Table 2).
The patterns of responses of 231-Luc+ and 435-Luc+ tumors were
similar except that 435-Luc+ tumors were more sensitive to VEGF-A
depletion but more resistant to nab-paclitaxel than 231-Luc+ tumors.
Compared with the control group, bevacizumab alone inhibited
growth of 435-Luc+ tumors by 52% but had insignificant effect on
Figure 1. The kinetics of metastatic spread of orthotopic 231-Luc+ tumors demonstrates preexisting metastases at the time of the
treatment. Lymphatic and hematogenous metastasis was assessed in mice (n = 4 per group) bearing orthotopic 231-Luc+ tumors killed
when averaged tumors volumes ranged from 100 to 1800 mm3. Metastatic incidence and burden were detected using firefly luciferase
activity normalized to total mg of protein per organ of three ipsilateral LNs (ILNs) and one lobe of the lung. (A) The metastatic burden of
the ILN and lung is presented as the mean luciferase activity per group ± SE. Note that 100% of mice bearing 231-Luc+ tumors of
volume equal or larger than 250 mm3 had lymphatic and pulmonary metastases. The black arrow indicates tumor volume at which
treatment began in experiments presented in Figures 2 and 3 depicted later. Luciferase measurements of lysates derived from ILN
(B) and lung (C) of individual mice were plotted on a semilog graph as a function of tumor volume and subjected to linear regression
analysis. Each dot represents tumor volume and its respective metastatic burden of an individual mouse as detected by luciferase ac-
tivity. The squared Pearson correlation coefficient (R2) derived from the linear regression analysis is shown on each graph.
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advanced 231-Luc+ tumors (Figure 2, A and C). A low dose of nab-
paclitaxel (10 mg/kg) suppressed growth of 435-Luc+ and 231-Luc+
tumors by 70% and 78%, respectively. A high dose of nab-paclitaxel
(30 mg/kg) suppressed growth of 435-Luc+ and 231-Luc+ tumors by
92% and 82%, respectively (Figure 2, B and D; Table 2). Despite
significant tumor suppression in both models by the 30-mg/kg dose,
tumors recurred in all mice within 2 weeks after cessation of therapy
and, by the end of experiments, approximated the size in saline-treated
mice (Figure 2D).
The response to chemotherapy including reduced incidence of tu-
mor recurrence was significantly improved in mice receiving both beva-
cizumab and nab-paclitaxel. In the groups receiving the 10-mg/kg
dose, the extent of tumor inhibition was raised from 70% to 77%
to 91% to 98%, and tumor growth delay (TGD) extended from 38
to 42 days to longer than 80 days. Significantly, 33% mice (2/7) with
231-Luc+ tumors had CRs. Nab-paclitaxel at 30 mg/kg combined
with bevacizumab raised the response rate to 99%. Within this group,
71% of mice (10/14) had complete tumor eradication. This was
verified by palpation, gross observations, and assessment of residual
luciferase activity in the tumor-implanted MFP. A high incidence of
tumor eradication by the combined therapy was reproduced in two
independent experiments (n = 14), both of which yielded statistically
significant differences between nab-paclitaxel alone and the combined
therapy, with P = .007 to P = .001 (Table 2). To assess whether the
antitumor effect of the combined nab-paclitaxel and bevacizumab
therapy was additive or synergistic, we used the CompuSyn software
based on the calculations of synergy outlined by Chou et al. [32] for
Taxol combined with other chemotherapeutic drugs. A comparison of
tumor reduction by a singular drug versus combination therapy re-
vealed a confidence interval of 0.002. On the basis of this software
analysis, values less than 1 indicate the synergy between two drugs.
Therefore, the antitumor effect of nab-paclitaxel and bevacizumab
combined therapy is synergistic.
In summary, two courses of 30 mg/kg of nab-paclitaxel combined
with bevacizumab inhibited advanced orthotopic 435-Luc+ and 231-
Luc+ breast tumors by more than 90%, with complete eradication of
Table 1. Incidence of Metastasis in 231-Luc+ Model during Tumor Progression*.
Tumor Volume† ILN‡ CLN‡ Lung Brain Heart Kidney cMFP‡ Ovary
92 3/4 (75%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 1/4 (25%) 0/4 (0%) 0/4 (0%) 0/4 (0%)
149 1/4 (25%) 1/4 (25%) 3/4 (75%) 0/4 (0%) 1/4 (25%) 1/4 (25%) 1/4 (25%) 0/4 (0%)
262 4/4 (100%) 0/4 (0%) 4/4 (100%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 1/4 (25%) 0/4 (0%)
485 4/4 (100%) 0/4 (0%) 4/4 (100%) 1/4 (25%) 1/4 (25%) 1/4 (25%) 2/4 (50%) 1/4 (25%)
1130 6/6 (100%) 2/7 (29%) 9/9 (100%) 1/4 (25%) 1/4 (25%) 1/4 (25%) 0/4 (0%) 0/4 (0%)
1804 10/10 (100%) 6/8 (75%) 9/9 (100%) 0/4 (0%) 3/4 (75%) 3/4 (75%) 2/4 (50%) 2/4 (50%)
Highlighted row indicates the average tumor volume at which treatment begins.
*Tissue lysates were from axillary, brachial, and inguinal LNs from the ipsilateral or contralateral sides, one lung, one lobe of the liver, whole brain, whole heart, ipsilateral kidney, and ovary, and
contralateral MFPs were assayed for luciferase activity. Samples with readings greater than 800 light units per 10-μl lysate were considered positive. Background luminescence was less than 100 light units
and was determined from tissue lysates from non–tumor-bearing mice. Results are presented as number of mice with positive organs per total number of mice at each average tumor size. Percentage of
positive mice in each group is noted in parentheses.
†Average tumor volume in cubic millimeters.
‡ILN, CLN, and cMFP denote ipsilateral lymph nodes, contralateral lymph nodes, and contralateral mammary fat pad, respectively.
Table 2. The Effect of Bevacizumab and Nap-paclitaxel on Tumor Growth.
Treatment n* Drug Dose (mg/kg) Mean Tumor
Volume (mm3)
% Inhibition
of Control
TGD† vs Control % CR‡ Statistical Significance§ vs
Control ABX
MDA-MB-435 Luc+
Control 8 — 2157 ± 173 — — 0 — —
Bev¶ 7 4 1030 ± 143 52.3 20 0 <.001 —
ABX¶ 8 10 642 ± 110 70.2 38 0 <.001 —
ABX + Bev 7 10/04/11 174 ± 19 91.9 >80 0 <.001 <.001
Control 8 — 2151 ± 171 — — 0 — —
Bev 7 4 1030 ± 143 52.1 20 0 <.001 —
ABX 8 30 180 ± 15 91.7 >80 0 <.001 —
ABX + Bev 7 30/4 112 ± 33 94.8 >80 0 <.001 .05
MDA-MB-231 Luc+
Control 7 — 2095 ± 144 — — 0 — —
Bev 7 4 1332 ± 132 36.4 20 0 .006 —
ABX 7 10 469 ± 100 77.6 42 0 <.001 —
ABX + Bev 7 10/04/11 26 ± 17 98.8 >90 33.3 <.001 .001
Control 16 — 1973 ± 214 — — 0 — —
Bev 14 4 1933 ± 134 2.0 6 0 NS# —
ABX 14 30 347 ± 59 82.4 55 0 <.001 —
ABX + Bev 14 30/4 12 ± 9 99.0 >90 71.4 <.001 <.001
*n indicates the number of mice per experimental group.
†TGD (tumor growth delay) is defined as a number of days that delayed the mean tumor volume per group reaching 1000 mm3 compared with the saline-treated control group.
‡Complete response was defined as absence of palpable tumor at the original tumor injection site for the entire length of the experiments (90-95 days).
§Statistical significance was assessed using a Student’s t test. P < .05 was considered to be significant.
¶Bev, ABX, and ABX + Bev denote treatment with bevacizumab, nab-paclitaxel, and combination of the two drugs, respectively.
#NS indicates that results were not statistically significant.
Neoplasia Vol. 13, No. 4, 2011 Nab-paclitaxel/Bevacizumab Efficacy Againts Large Tumors Volk et al. 331
231-Luc+ tumors in 71% of the mice. The treatment was well toler-
ated with no mortality or morbidity observed in any of the treated
mice (approximately 130 mice in total). These data show in two ortho-
topic models that the combined nab-paclitaxel/bevacizumab therapy
is effective against advanced breast tumors.
Nab-paclitaxel/Bevacizumab Therapy Caused Regression
of Existing Metastases in Advanced BC Models
Metastases is the main cause of mortality from cancer [34]. Be-
cause the combined therapy was highly efficacious against advanced
primary tumors, we sought to determine its effect on metastases in the
same models. The 231-Luc+ tumors disseminate primarily through
lymphatics [30], whereas 435-Luc+ tumors undergo mainly hema-
togenous metastasis [16,35]. Thus, analysis in these two models allows
for assessment of the antimetastatic efficacy in tumors disseminat-
ing through either route. To this end, mice with tumors of 450 to
600 mm3 in volume (7-16 mice per group) were treated with saline,
10 or 30 mg/kg of nab-paclitaxel alone or combined with bevacizumab
(4 mg/kg). Mice were killed when control tumors reached 1800 mm3,
followed by measurement of luciferase activity in LN and lung ex-
tracts to quantify incidence and metastatic burden, as previously de-
scribed [16,30].
In the 435-Luc+ model, positive LN and pulmonary metastases
were detected in 12.5% and 100% of control mice, respectively (Fig-
ure 3A). Bevacizumab alone had no effect on either LN or lung me-
tastasis, whereas nab-paclitaxel alone increased, rather than decreased,
both incidence and burden of LN metastases (Figure 3, A and B).
The incidence was raised from 12.5% in the control group to 75%
in the group treated by nab-paclitaxel at does of 10 mg/kg (P =
.041). A similar trend was detected in mice treated with 30 mg/kg
(25% higher than control; Figure 3A). Importantly, combination ther-
apy suppressed both incidence and LN metastatic burden by reduc-
ing it to basal or below basal level. For instance, in mice treated
with 10 mg/kg, the mean luciferase activity in LN decreased from
194,126 ± 47,252 RLU/mg protein in chemotherapy-alone group
to 0 ± 0 RLU/mg in the combination group (P < .001).
With regard to lung metastasis in the 435-Luc+ model, neither
incidence nor burden was affected by a single nab-paclitaxel treat-
ment. However, when nab-paclitaxel at the dose of 10 mg/kg was
combined with bevacizumab, the incidence and burden of lung me-
tastasis were reduced by 57% and 93%, respectively (Figure 3, A and
B). This result was statistically significant (P = .026) compared with
either control or nab-paclitaxel alone group (Figure 3B). The com-
bination group treated with 30 mg/kg of nab-paclitaxel showed a
similar trend in reduction of incidence, but the values did not reach
statistical significance.
The effect on LN metastasis was of major interest in this study
because it is well established that lymphatic vessels are the primary
route for dissemination of BCs [36]. As we previously described [16]
and show here (Figure 1), orthotopically implanted 231-Luc+ breast
Figure 2. Combined bevacizumab and nab-paclitaxel therapy enhances tumor growth inhibition in mice with orthotopic advanced tu-
mors. Mice were orthotopically implanted with 435-Luc+ (A, B) or 231-Luc+ (C, D) tumors and grown to an average tumor volume of 450
to 600 mm3. Tumor-bearing mice undergoing monotherapies were treated with bevacizumab (4 mg/kg, two cycles) (A–D), nab-paclitaxel
(10 mg/kg, daily for five consecutive days cycle) (A and C), or nab-paclitaxel (30 mg/kg, daily for five consecutive days) (B and D). Com-
bined treatment with bevacizumab and 10 or 30 mg/kg of nab-paclitaxel (daily for five consecutive days for two courses) consisted of i.p.
injections of bevacizumab biweekly starting 24 hours after the first nab-paclitaxel injection for the duration of the study. Black arrows in
all panels indicate the start of each cycle. The red CR corresponds to the percentage of CRs in the combination group. Each group
consisted of 7 to 16 mice. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation.
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carcinoma line is an excellent model for human BC because it dem-
onstrates 100% incidence of LN metastases in untreated mice. On
the basis of the Fisher exact test, the incidence of LN metastasis was
not significantly affected by monotherapy with bevacizumab or nab-
paclitaxel administrated at either the 10- or the 30-mg/kg dose (Fig-
ure 3C , left panel ). However, the metastatic burden in LN was re-
duced in groups treated with bevacizumab alone (P = .005) as well as
in groups treated with 10 and 30 mg/kg nab-paclitaxel (P = .003 and
Figure 3. Bevacizumab suppresses antimetastatic effects of nab-paclitaxel therapy in mice with advanced tumors. Metastasis to the LNs
and lungs was assessed in mice bearing advanced orthotopic 435-Luc+ (A and B) and 231-Luc+ (C and D) tumors after monotherapy
with 10 or 30 mg/kg nab-paclitaxel or combined with bevacizumab administrated at 4 mg/kg. Each group consisted of 7 to 16 mice.
Metastatic burden was measured by luciferase activity normalized to total milligrams of protein in lysates from axillary, brachial, inguinal
LNs, and one lobe of the lung. Metastatic incidence in the LNs and lungs is represented in the left panel in A, B, C, and D. Data pre-
sented at the center and right panels are the metastatic burden of the LNs and lungs treated with 10 or 30 mg/kg ABX, respectively.
Metastatic burden of individual mice is represented by the dots, and the black bars indicate the average metastatic burden ± SE per
group. Statistical significance was assessed by Fisher exact test and Wilcoxon rank sum test for incidence and burden, respectively.
P values shown black represent statistically significant changes in incidence or metastatic burden.
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P = .001, respectively). Importantly, the combination therapy con-
sisting of 30 mg/kg of nab-paclitaxel and bevacizumab eradicated
both LN and lung metastases in 83% (10/12) and 58% (7/12) of
the mice (n = 12 per group). These results were highly statistically
significant compared with either control (P < .002) or 30 mg/kg
of nab-paclitaxel alone group (P < .001 and P < .002 for inhibition
of LN and lung metastasis, respectively). To assess whether the anti-
metastatic effect of the combined nab-paclitaxel and bevacizumab
therapy was additive or synergistic, we used the CompuSyn software
described in the Materials and Methods. The analysis determined a
confidence interval less than 0.001 for the effect of the combination
therapy on LN metastasis, demonstrating that this effect is highly
synergistic compared with nab-paclitaxel or bevacizumab alone.
The effects on lung metastasis did not reach synergistic level, possibly
because of the relatively low metastatic burden in the lungs at the
time of analysis of this model.
In summary, the nab-paclitaxel/bevacizumab therapy showed sig-
nificantly improved antimetastatic efficacy in both models of ad-
vanced 435-Luc+ and 231-Luc+. The combined therapy was the least
efficacious against lung metastasis in the 435-Luc+ model, resulting in a
reduced incidence by 29% compared with nab-paclitaxel treated mice.
The combined therapy was the most efficacious against LN metastasis
in the 231-Luc+ model, resulting in 83% and 92% reduction in inci-
dence and burden, respectively, whereas the monotherapy of either
drug was ineffective.
Effect of Sequence of Drugs’ Administration on Efficacy
of Combined Therapy
The optimal schedule for sequence of nab-paclitaxel/bevacizumab ad-
ministration was determined in the 435-Luc+ tumor model because this
model was more responsive to bevacizumab. Mice bearing 450 mm3-
sized 435-Luc+ tumors were treated with saline (control; group 1) or
with nab-paclitaxel (10 mg/kg) and bevacizumab (4 mg/kg) using three
distinct regimens outlined in Figure 4A. Group 2 received bevacizumab
immediately after cessation of nab-paclitaxel treatment. Group 3 re-
ceived the antibody concurrently with nab-paclitaxel, and both drugs
were terminated simultaneously. Group 4 also received both drugs
concurrently, but the bevacizumab therapy continued until the last
day of the experiment (118 days).
The results showed that the sequential regimen (group 2) was the
least efficacious, suppressing tumor growth by 80% compared with
95% and 98% inhibition in groups 3 and 4, respectively (Figure 4B).
The superior outcome after concurrent cytotoxic/anti–VEGF-A ther-
apy suggested that VEGF-A is elevated immediately on initiation of
therapy and plays an important role in chemoresistance. This hy-
pothesis was supported by comparison of VEGF-A expression in
control- and nab-paclitaxel– (10 mg/kg) treated tumors harvested
at days 0 to 8 after treatment. Tumors harvested 3 to 5 days after treat-
ment showed significant dose-dependent increases in VEGF-A ex-
pression in treated but not in control tumors. Quantitative analysis
performed using the ImageJ software showed widespread VEGF-A in-
crease detected in all treated but not the control tumors (Figures 4, C
and D, and W1). This suggests that, for optimal results, anti–VEGF-A
antibody and chemotherapy should be administrated concurrently.
Basis for Synergistic Effect of Nab-paclitaxel and
Bevacizumab Therapy
We next sought to determine the mechanisms underlying the syn-
ergistic effects of combined therapy. Paclitaxel and nab-paclitaxel have
been previously shown to induce expression of VEGF-A in tumor cells
in vitro [16,37]. Figure 4 shows that nab-paclitaxel also induces
VEGF-A tumor cells in vivo. VEGF-A counteracts the efficacy of cyto-
toxic drugs by promoting tumor cell survival [16]. This effect might
be mediated through VEGF-A–dependent activation of the NF-κB
pathway [37] that upregulates numerous proteins essential for cell sur-
vival [38]. This mechanism might account for a significantly better
outcome observed in combination groups.
To test this hypothesis, we first determined activation of the NF-
κB pathway by nab-paclitaxel in cultured 231-Luc+ cells. Cells were
treated with escalating doses of nab-paclitaxel (0-30 nM) for 8 to
48 hours followed by Western blot analysis. Eight hours after ex-
posure to nab-paclitaxel, the expression of phosphorylated p-p50
and p-p65 subunits of the NF-κB as well as Bcl-xL was significantly
increased (Figure 5A). Later time points (24 and 48 hours) showed
significant increases in p-Akt and p-p44/42, although the expression
of nonphosphorylated counterparts remained unchanged (Figures 5A
and W2). NF-κB activation by nab-paclitaxel was further confirmed
by measuring inflammatory cytokines IL-6 and IL-8, the down-
stream products of this pathway. Cytokines from the conditioned
medium of 231-Luc+ cells treated for 72 hours with nab-paclitaxel
(2.5-30 nM) were measured using Luminex. Nab-paclitaxel signifi-
cantly increased expression of both IL-6 and IL-8 in a dose-dependent
manner up to maximum of 20- to 22-fold (Figure 5B). TNF-α was
also increased from undetectable level to 9.5 × 103 pg normalized
per 1 × 106 cells (Figure 5C ). These findings demonstrate that nab-
paclitaxel activates the NF-κB pathway in tumor cells leading to in-
creased expression of IL-6, IL-8, TNF-α, Bcl-2, and Bcl-xL, all of
which may trigger reactionary angiogenesis [39] and promote survival
of tumor cells [38].
We next determine whether nab-paclitaxel behaves similarly in vivo.
Groups of 231-Luc+–bearing mice (n = 4) with advanced tumors
(500 mm3) were treated with nab-paclitaxel (30 mg/kg) followed by
analysis on the third, fifth, and eighth days after initiation of the treat-
ment. Tumor lysates and sections were analyzed for the expression of
NF-κB and prosurvival proteins using Western blot and immunohis-
tochemistry, respectively. The expression of several inflammatory and
prosurvival proteins including p-p50, p-p44/42, p-Akt, Bcl-2, and
Bcl-xL has significantly increased after nab-paclitaxel treatment. The
highest increase for most targets was on the eighth day after treatment
(Figures 6A and W3). Of all targets, up-regulation of Bcl-2 and Bcl-xL
was the most conspicuous, and these targets were confirmed by im-
munohistochemistry. Control tumors displayed homogenous but weak
Bcl-2 expression and strong but sporadically expressed Bcl-xL (Fig-
ure 6B, Control ). Three days after nab-paclitaxel treatment, the expres-
sion of both proteins was slightly decreased or unchanged. However, at
the fifth and eighth days after treatment, the expression of both pro-
teins was significantly increased (Figure 6B). Collectively, these data
suggest that chemotherapy-induced expression of VEGF-A followed
by activation of the NF-κB pathway play an important role in che-
moresistance of advanced tumors.
Discussion
This study demonstrates that combination of nab-paclitaxel and
bevacizumab is highly efficacious against advanced orthotopic breast
tumor xenografts and preexisting lymphatic and visceral metastases.
The improved efficacy of combined therapy was demonstrated by
substantial tumor suppression, delayed time to progression, and, in
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the 231-Luc+ model, eradication of both large-sized tumors and
metastases. These results provide novel evidence for a mechanism un-
derlying the synergy between two drugs. We show that chemoresis-
tance was due to the up-regulation of VEGF-A followed by the
activation of the NF-κB pathway in tumor cells leading to the pro-
duction of inflammatory cytokines and prosurvival proteins that di-
minish the chemotherapeutic efficacy. These data provide a basis for
combining nab-paclitaxel and anti–VEGF-A therapies to sustain ther-
apeutic gains.
The concept of improving efficacy of chemotherapy by combining
with antiangiogenic drugs has been previously shown in several stud-
ies [16,40]. However, most previous studies were performed in mice
with small-sized (100-150 mm3) tumors, which precludes direct
comparison to our results. We reviewed 65 published studies that
assessed chemotherapeutic effects in BC models (Table W1). Only
two previous studies challenged mice bearing tumors larger than
400 mm3 [41,42]. We sought to impart a better realism to xeno-
graft models by delaying the treatment until tumors reached 450
to 600 mm3. To our knowledge, this is the first report of CR sus-
tainable longer than 100 days occurring in more than 70% of mice
bearing advanced (>450 mm3) orthotopic xenografts. Combination
therapy also significantly suppressed advanced 435-Luc+ tumors, al-
though no CRs were observed. This could be due to the genetic
differences between 231-Luc+ and 435-Luc+ tumors that would be
associated with increased resistance to paclitaxel, survival, or meta-
static potential. This is indirectly supported by the propensity of
435-Luc+ tumors to undergo hematogenous metastasis, which re-
quires a superior ability to survive in the bloodstream [43]. Never-
theless, more than 90% suppression of 231-Luc+ and 435-Luc+
advanced tumors and 71% of CR in mice with 231-Luc+ tumors
Figure 4. Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor
growth and metastasis. (A, B) Mice bearing 435-Luc+ tumors of 450 mm3 in volume were treated with bevacizumab (4 mg/kg) using
three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illus-
tration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel
followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were
discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and
for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean
tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C,
bottom) tumors were stained with anti–VEGF-A antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei.
Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D,
bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of
representative images in (C) are shown. All images were acquired at a magnification of ×200.
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represent significantly improved outcome in both models than is typ-
ically reported for combined Cremophor-based paclitaxel/anti–VEGF-
A therapy [17].
Metastatic BC is currently considered incurable [44–46], with a
median survival of 18 to 24 months [45], and palliative treatment
is offered as the only option [46]. We show that the combined nab-
paclitaxel/bevacizumab therapy significantly suppressed or eradicated
preexisting lymphatic and pulmonary metastases in mice bearing 450
to 600 mm3 human breast xenografts. Eradication of preexisting
metastases demonstrated in these orthotopic advanced BC models
Figure 6. Nab-paclitaxel therapy activates prosurvival and inflammatory pathways in advanced orthotopic 231-Luc+ tumors in vivo. Mice
bearing orthotopic 231-Luc+ tumors of equal or higher than 500 mm3 in volume were treated with daily injection of 30 mg/kg of nab-
paclitaxel for 3, 5, and 8 days. (A) Western blot analysis of the expression of phosphorylated and nonphosphorylated forms of NF-κB
p50, p44/42, Akt, and unmodified Bcl-2 and Bcl-xL in mixed lysates from tumors harvested on days 3, 5, and 8 after the beginning of
treatment (n = 4 mice per group). β-Actin was used as a loading control. Note upregulated expression of p-p50, p-Akt, Bcl-2, and Bcl-xL
as indicated by the asterisks. (B) Frozen tumor sections from mice treated with nab-paclitaxel for 3, 5, and 8 days were stained with
antibodies against prosurvival proteins, Bcl-2 (top row) and Bcl-xL (bottom row). The center of all treated tumors was highly necrotic and
devoid of positive staining for any targets. All images were acquired at 200× magnification from the margins of the tumor. Note the
significant time-dependent increase in the expression of both Bcl-2 and Bcl-xL after 3 to 8 days of nab-paclitaxel treatment.
Figure 5. Treatment of breast carcinoma 231-Luc+ cells with nab-paclitaxel induces inflammatory response. (A) 231-Luc+ cells were plated
at a density of 2.5 × 106 cells per well in six-well plates and treated with a nab-paclitaxel (0-30 nM) for 8 (left), 24 (center), and 48 (right)
hours. Control and treated 231-Luc+ cell lysates were analyzed by Western blot for changes in the phosphorylated and nonphosphorylated
forms of NF-κB p50, NF-κB p65, Erk p44/42, Akt, and unmodified Bcl-xL. β-Actin served as a loading control. The asterisks represent targets
with significant changes in response to nab-paclitaxel treatment. (B, C) Production of inflammatory cytokines by 231-Luc+ cells treated for
72 hours with nab-paclitaxel (0-30 nM) was determined in the conditioned medium by Luminex assay. Note that IL-6 and IL-8 (B) and TNF-α
(C) are highly upregulated in response to nab-paclitaxel treatment in a dose-dependent manner. Data are presented as the mean cytokine
concentration normalized per number of viable tumor cells that are derived from two independent experiments ± SE.
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challenges the current dogma of incurability of metastasis and suggests
that this strategy may cure patients with advanced metastatic disease.
The ability of anti–VEGF-A antibody to suppress the prometastatic
effect of chemotherapy suggests that VEGF-A is primarily responsible
for the paclitaxel-induced prosurvival effects. Nab-paclitaxel–dependent
induction of VEGF-A has been previously demonstrated in our studies
[16] and confirmed by other groups [37]. Currently, the mechanisms
leading to VEGF-A up-regulation by paclitaxel and the consequences
of VEGF-A signaling for tumor recurrence are poorly understood. We
hypothesized that chemotherapy-induced VEGF-A might also partici-
pate in the hyperactivation of the NF-κB pathway in tumor cells as
well as being a product of NF-κB activation. We show here that ex-
posure to nab-paclitaxel correlates with activation of the NF-κB as
demonstrated by the overexpression of its target inflammatory and pro-
survival proteins including IL-6, IL-8, TNFα, Bcl-2, and Bcl-xL (Fig-
ures 5 and 6). This is consistent with a wealth of reported evidence
demonstrating NF-κB activation in tumor cells by various chemothera-
peutic drugs including Cremophor-based paclitaxel [47–49]. Paclitaxel-
dependent increased expression of NF-κB–dependent inflammatory
[47] and prosurvival proteins [49] has been widely reported in various
tumor lines. NF-κB activation in tumor lines has been shown to cor-
relate with the up-regulation of VEGF-A [9,16], p-Akt [49], Bcl-2, and
Bcl-xL [50]; increased tumor cell survival [51]; metastasis [52]; and re-
sistance to chemotherapy [51]. Our data show that nab-paclitaxel is
similar to Taxol and other cytotoxic drugs with regard to increasing
the functional capacity of the NF-κB and its consequences for tumor
progression. On the basis of these reports and the data presented here,
we postulate that the tumor-promoting effects of nab-paclitaxel, in-
cluding resistance to apoptosis and increase in metastasis, are due to
VEGF-A–induced and NF-κB–mediated signaling that prevents cyto-
toxic cell death whereby resisting chemotherapy. Consequently, deple-
tion of VEGF-A concurrently with chemotherapy eliminates the first
stimulus for NF-κB activation, thus permitting the full potential of a
cytotoxic drug to materialize.
Conclusions
In summary, we show here that nab-paclitaxel/bevacizumab therapy
eradicates large orthotopic breast tumors and preexisting LN and pul-
monary metastases. The optimal results were achieved by concurrent
but not sequential bevacizumab administration, implicating VEGF-A
as an immediate response factor for resistance to chemotherapy. Low
doses of chemotherapy were largely ineffective against advanced pri-
mary tumors and occasionally increase metastases. The mechanism
of resistance to nab-paclitaxel involves activation of the NF-κB path-
way in malignant cells that increased production of inflammatory
mediators and prosurvival Bcl-2 and Bcl-xL proteins. This study sug-
gests that two major factors in prevention of tumor recurrence are
efficient delivery of cytotoxic drugs and concurrent suppression of
chemotherapy-activated prosurvival traits endowed by VEGF-A ini-
tiated activation of the NF-κB pathway. The high efficacy of this ap-
proach against large metastatic BC xenografts strongly advocates for
adapting nab-paclitaxel/bevacizumab regimen in the clinics.
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Table W1. Reported Inhibition of Human Xenografts by Various Regimens Including Chemotherapeutic Drugs Alone or in Combination with Other Antiangiogenic and Other Therapies.
No. BC Cell Line(s) TV (mm3)
Before Treatment
Drugs and Doses Length of
Study (d)
% Maximal
Inhibition
% CR PMID
Assessment of combination therapy using paclitaxel and anti-VEGF drugs in various models
1 MDA-MB-231 Luc+ 310 Nab-paclitaxel (10 mg/kg); bevacizumab (4 mg/kg) 110 97 80* 18516298
2 MDA-MB-231 300 DC101 (2 mg/kg); vinblastin (0.5 mg/kg);
adriamycin (1 mg/kg); cisplatin (1-2 mg/kg);
cyclosporine A (10 mg/kg); verapmil (20 mg/kg)
130 93 0 11801563
3 MDA-MB-231 and MDA-MB-435 150-200 Cyclophosphamide (10-150 mg/kg);
DC101 (800 μg/dose)
120-130 75 0 12019144
4 MCF7 ∼50 murine 4D5 antibody; rhuMab 4D5 HER-2
antibody (1-3 mg/kg); cisplatin (0.25-0.75 mg/kg);
doxorubicin
25 90 0 9811454
5 MX-1 100 Docetaxel (5, 10, or 15 mg/kg); 5-fluorouracil (100 mg/kg);
doxorubicin (4 mg/kg); SU11248 (40 mg/kg)
60-90 90 0 14578466
6 GEO 200-300 ZD6474 (150 mg/kg); paclitaxel (20 mg/kg) 100 99 40 12684431
7 CWR22R 100-200 rhuαVEGF (5 mg/kg); paclitaxel (6.25 mg/kg) 40 98 0 12374693
8 Hey A8, SKOVip1 100 AEE788 (25 or 50 mg/kg); paclitaxel (75 or 125 mg/kg) 130 95 0 16000591
9 OVCAR3 See below† Mouse mAb (A4.6.1) (5 μg/g); paclitaxel (20 μg/g) n/a 83 0 12414537
10 OVCAR3 See below† VEGF Trap (10 mg/kg); paclitaxel (10 mg/kg) 150 97 0 16203789
11 PC3, A375, A431, A2780, MX-1,
HCT116, and MV522
150 JNJ-17029259 (25-125 mg/kg); paclitaxel (30 mg/kg);
doxorubicin (3 mg/kg)
60 96 0 15322256
12 PC3-3M-MM2 Palpable DC101 (1 mg/kg); paclitaxel (0.25 mg/kg) 28 97 0 12171905
13 253J-BV See below‡ DC101 (1 mg/kg); paclitaxel (10 mg/kg) 56 82 0 10914704
Assessment of chemotherapy and other experimental treatments in breast models
14 MDA-MB-231, Cal-51 and MCF7 200 Motesanib (75 mg/kg); docetaxel (20 mg/kg);
doxorubicin (2.5 mg/kg); tamoxifen (30 mg/kg)
50 66 0 19118038
15 MDA-MB-231, MDA-MB-468,
T47D, and MCF7
50-80 Paclitaxel (20 mg/kg) 10-12§ 75 0 19239702
16 MDA-MB-231 50-100 F16-IL2 (20 μg), IL-2 (6.6 μg), doxorubicin (1 or 4 mg/kg),
paclitaxel (1 or 5 mg/kg)
70-80 90 0 18927291
17 MDA-MB-231 100-150 PEG-Doxorubicin (3 mg/kg) encapsulated in microbubble
followed by ultrasound
90 ∼90 0 17623798
18 MDA-MB-231 150-200 Cyclophosphamide (20 mg/kg); Tirapazamine (25 mg/kg) 85-90 60 0 16452226
19 MDA-MB-231/LM2-4 150-200 UFT (15 mg/kg); cyclophosphamide (20 mg/kg) 46 50 0 16585158
20 MDA-MB-231-H2N 250 Cyclophosphamide (100 mg/kg); Trastuzumab (20 mg/kg) 140 75 0 16467105
21 MDA-MB-231 100 Parthenolide (40 mg/kg) and docetaxel (5 mg/kg) 42§ 29 0 15956258
22 MDA-MB-231, BT-474, ZR-75-1 100 AS Bcl-2 and AS Bcl-xL ODNs (5 mg/kg); paclitaxel and
docetaxel (10 mg/kg); mitomycin C (2 mg/kg)
36§ 90 0 16280040
23 MDA-MB-231 50-100 Diets supplemented with 2%-5% fish or corn oil;
doxorubicin (5 mg/kg)
30-35 80 0 12296973
24 MDA-MB-231 100 5-Fluorouracil (30 mg/kg); adriamycin (2.5 mg/kg);
TNP-470 (200 mg/kg)
45 15 0 7693335
25 MDA-MB-435 100 Paclitaxel (10 mg/kg); SC144 (25-100 mg/kg) 35 80 0 19322070
26 MDA-MB-435 90-130 Doxorubicin (8 mg/kg) 39 85 0 14696623
27 MDA-MB-435 100-150 RGD (15 or 25 mg/kg); paclitaxel (10 mg/kg) 18§ 66 0 18373091
28 MDA-MB-435 100 Irinotecan (5 mg/kg); CHIR-124 (10 or 20 mg/kg) 36§ 53 0 17255282
29 MDA-MB-435 100 mg Docetaxel (25 mg/kg); S-1 (8.3 mg/kg) 25§ 67 0 16685389
30 MDA-MB-435 100-200 Adriamycin (5 mg/kg); etoposide (15 mg/kg);
salvicine (6-24 mg/kg)
42 83 0 15867248
31 MDA-MB-435 25-50 3G4 (100 μg); docetaxel (10 mg/kg) 35 93 0 15899833
32 MDA-MB-435/LCC6 100-150 g Bcl-2 AS G3139 and RP ODNs (5 or 10 mg/kg);
doxorubicin and liposomal doxorubicin (5 or 10 mg/kg)
70 80 0 10914739
33 MDA-MB-435/LCC6MDR1 See below§ Paclitaxel (12 mg/kg); OC144-093 (30 mg/kg) 35-30§ 60 0 10850444
34 MCF7 50-150 Seliciclib (400 mg/kg); doxorubicin (1.5 mg/kg) 18§ 70 0 19003963
35 MCF7 Palpable Lysine (100 mg/kg); RHL (50 or 100 mg/kg);
Taxol (10 mg/kg)
35 85 0 19343002
36 MCF7 and MDA-MB-435 100-200 8-quinolinol (20 mg/kg); paclitaxel (15 mg/kg) 60-70 90 0 18506619
37 MCF7 100 Dopamine (50 mg/kg); doxorubicin (5 mg/kg) 14§ 37 14 18413843
38 MCF7 100 Cisplatin (4, 8 mg/kg); paclitaxel (5, 10 mg/kg);
adriamycin (2.3, 4.7 mg/kg)
28§ 65 0 18593369
39 MCF7 and MCF7 HER2-18 150-200 Tamoxifen (500 μg/dose); gefitinib (100 mg/kg) 42-56 90 0 18245484
40 MCF7/Dox 100 Doxorubicin (5 mg/kg); 2-methoxyestradiol (30 mg/kg) 28 90 0 18253735
41 MCF7Ca 200 Androstenedione; letrozole 34 weeks 80 0 18559495
42 MCF7 50 Siramesine (6.5 mg/kg); vincristine (30 μg/kg) 14 70 0 17332352
43 MCF7 100-200 PDTC (60 mg/kg); Paclitaxel (10 mg/kg) 35 60 0 17965935
44 MCF7 Palpable Doxorubicin (5 mg/kg); cyclophosphamide (100 mg/kg) 26 75 0 15667832
45 MCF7HER2 50-100 Trastuzumab (0.03-10 mg/kg); liposomal
doxorubicin (1.5-12.5 mg/kg)
50 99 0 15948035
46 MCF7 5-10 mm in diameter Suramin (10 mg/kg); paclitaxel (15 mg/kg) 90 ∼90 50 15447990
47 MCF7 200 CCI-779 (10 mg/kg); Tamoxifen (500 μg/mouse) 17§ 75 0 15585641
48 MCF7 and MDA-MB-468 Tumor mass of
44-68 mg
Dexamethasone (0.1 mg/day); carboplatin (120 mg/kg);
gemcitabine (160 mg/kg)
30-70 50 0 15014014
49 Parental MCF7 and various
derivatives
50-75 Photress (8, 12, and 18 mg/kg); doxorubicin (8 mg/kg) — 75 0 15377855
Table W1. (continued )
No. BC Cell Line(s) TV (mm3)
Before Treatment
Drugs and Doses Length of
Study (d)
% Maximal
Inhibition
% CR PMID
50 MCF7/adr 65 Doxorubicin (4 mg/kg); tetrandrine (30 mg/kg) 32§ 58 0 11818209
51 MCF7 100 CBR96-doxorubicin (3.3 mg/kg); paclitaxel (10 mg/kg) 35 95 0 11477565
52 MCF7 50-100 Doxorubicin (5 mg/kg); methotrexate (2 mg/kg);
VP-16 (20 mg/kg); 5-fluorouracil (16 mg/kg);
vinblastine (0.8 mg/kg); cyclophosphamide (80 mg/kg);
paclitaxel (15 mg/kg)
25§ 99 0 10327070
53 MCF7 50-100 Doxorubicin (6 or 8 mg/kg); BR64-doxorubicin (15 mg/kg) 70 87 0 1382845
54 MX-1 50-100 3176152HCl (10 or 30 mg/kg); paclitaxel (24 mg/kg);
carboplatin (50 mg/kg)
TGD¶ TGD 0 12201487
55 MX-1 and MAXF401 ∼500 Capecitabine (359 mg/kg); Docetaxel (7.5 mg/kg);
5′dFUrd (123 mg/kg); 5-Fura (13 mg/kg)
84 90 60 11309360
56 MX-1 50-100 Cryptophycin 52 (5 mg/kg); cryptophycin 55 (15 mg/kg);
doxorubicin (1.75 mg/kg); paclitaxel (24 mg/kg);
vionrelbine (7.5 mg/kg); gemcitabine (60 mg/kg);
5-fluorouracil (30 mg/kg)
23 days delay in
tumor growth
– 0 10972484
57 MX-1 50 MTA (100, 150, 200 mg/kg); methotrexate (0.8 mg/kg);
5-fluorouracil (30 mg/kg); doxorubicin (1.75 mg/kg);
paclitaxel (24 mg/kg)
40 TGD 0 10741729
58 BT474 100-200 Laptinib (30, 60, or 100 mg/kg); topotecan (6 or 10 mg/kg) 75 90 0 19047120
59 SKBR-3 300-500 Edotecarin (3 or 30 mg/kg); docetaxel (5 mg/kg);
capecitabine (370 mg/kg)
∼50 89 0 17089166
60 BCap37 0.6-0.7 cm in diameter Dexamethasone (1 mg/kg); paclitaxel (20 mg/kg) 18 93 0 16496381
61 NCI/ADR-RES 100 Evodiamine (10 mg/kg); paclitaxel (20 mg/kg) 75 63 0 15705600
62 KPL-4 and BT-474 100-200 Trastuzumab (15 and 7.5 mg/kg); Capecitabine (126 mg/kg);
5′-dFUrd (43 mg/kg); 5-FUrd (4.6 mg/kg)
35-40 47 0 11935213
63 KPL-4 See below† Docetaxel (5 or 10 mg/kg); 5′-dFUrd (60/kg);
tegafur (100 mg/kg)
34 55 0 11710628
64 MDA-MB-468 50-100 Cisplatin (1 mg/kg); doxorubicin (4 mg/kg);
p53 adenovirus (8.3 × 108 CIU/dose
25-30 90 0 10412949
*CR percentages higher than 0% are highlighted in bold.
†Treatment started 14 days after implantation of tumor cells.
‡Treatment started 21 days after implantation of tumor cells.
§Tumor burden was assessed by weight.
¶Assessed by TGD.
Figure W1. Nab-paclitaxel treatment of 435-Luc+ tumors significantly
induces VEGF-A expression. Frozen sections from tumor-bearing
mice treated with saline (control) or 10, 20, and 30 ng/ml of nab-
paclitaxel were stained with anti–VEGF-A antibodies. The mean fluo-
rescent intensity (MFI) of VEGF-A staining was then calculated using
ImageJ software as described in the Materials and Methods. The
MFIs of the experimental groups are expressed relative to the MFI
detected in tumors from control mice (8.44 ± 0.4 arbitrary units)
that was set to a value of 100. Data are presented as the MFI of five
independent fields±SE (n=3mice per experimental group). *P< .05
and ***P < .001 versus control as determined by Student’s t test.
Images were acquired at 200× magnification.
Figure W2. Analysis of elevated prosurvival and inflammatory protein expression induced by nab-paclitaxel treatment of 231-Luc+ cells
in vitro. Western blots of lysates from cultured 231-Luc+ cells treated for 8 (A), 24 (B), and 48 hours (C) with 0 to 30 nM of nab-paclitaxel
(ABX) or PBS (CTRL) were further analyzed by band densitometry using LAS-3000 Image-Reader and Multi Gauge V3.0 software. Only
target proteins displaying significant changes in expression by Western blot analysis (Figure 5A) were chosen for further analysis as
indicated by labels above each graph. Specific concentrations of ABX treatment are also indicated at the top of the figure. Data are
presented as percentage of the control 231-Luc+ cell lysates.
Figure W3. Analysis of highly upregulated prosurvival and inflammatory proteins induced by nab-paclitaxel treatment of 231-Luc+ tu-
mors. Densitometry was performed on Western blots of lysates from 231-Luc+ tumors ∼500 mm3 treated with 30 mg/kg nab-paclitaxel
for 2, 4, and 7 days and harvested 24 hours after cessation of each treatment. Shown are analyses of p-NF-κB p50 (A), p-Akt (B), Bcl-2 (C),
and Bcl-xL (D) that were detected by Western blot to be highly upregulated by nab-paclitaxel treatment compared with saline-treated
control mice (Figure 6). Band strength was analyzed as described under the legend for Figure W2, and target protein expression is
presented as percentage of protein expression in tumor lysates from control saline-treated mice.
